IJMS, Vol. 24, Pages 12469: Drug Development from Natural Products Based on the Pathogenic Mechanism of Asthma

IJMS, Vol. 24, Pages 12469: Drug Development from Natural Products Based on the Pathogenic Mechanism of Asthma

International Journal of Molecular Sciences doi: 10.3390/ijms241512469

Authors: Min-Hee Kim Chun-Sik Bae So-Hyeon Bok Hyo-Seung Choi Taeho Ahn Seung-Sik Cho Dae-Hun Park

Asthma is a chronic inflammatory disease of the pulmonary system associated with many wheeze-to-sleep apnea complications that may lead to death. In 2019, approximately 262 million patients suffered from asthma, and 455 thousand died from the disease worldwide. It is a more severe health problem in children and older adults, and as the aging of society intensifies, the problem will continue to worsen. Asthma inducers can be classified as indoor and outdoor allergens and can cause asthma due to their repeated invasion. There are several theories about asthma occurrence, such as the imbalance between Th1 and Th2, inflammation in the pulmonary system, and the abnormal apoptosis/cell proliferation of cells related to asthma. Although there are many medications for asthma, as it is an incurable disease, the purpose of the drugs is only to suppress the symptoms. The current drugs can be divided into relievers and controllers; however, as they have many adverse effects, such as immune suppression, growth retardation, promotion of cataracts, hyperactivity, and convulsions, developing new asthma drugs is necessary. Although natural products can have adverse effects, the development of asthma drugs from natural products may be beneficial, as some have anti-asthmatic effects such as immune modulation, anti-inflammation, and/or apoptosis modulation.